Primary endometrial squamous cell carcinoma with molecular Characterization: A case report Authors: Yifei Zhan, Xiaojing Guo, Jinling Zhang Published: 2026 ABSTRACT Highlights•Primary endometrial squamous cell carcinoma is rare and challenging.•Clinicopathologic correlation is key to exclude cervical origin.•p53 abnormalities are common in reported cases.•Hormone receptor expression is often absent.Keywords: Primary endometrial squamous cell carcinoma, Immunohistochemistry, P53 abnormal, Raregynecologictumor Introduction Primary endometrial squamous cell carcinoma (PESCC) is an extremely rare type of endometrial cancer composed exclusively of cells with squamous differentiation. Its prevalence is approximately 0.1%(Chiang et al., 2015). According to the Fluhmann criteria proposed in 1928, the diagnosis of PESCC requires: (a) no coexistence of endometrial adenocarcinoma; (b) no continuity between the endometrial lesion and the cervical squamous epithelium; and (c) exclusion of primary cervical squamous cell carcinoma(Fluhmann, 1928). Currently, no specific staging system exists for PESCC; therefore, tumor staging is performed in accordance with the FIGO (International Federation of Gynecology and Obstetrics) staging system for endometrial carcinoma(Berek et al., 2023). We report a case of PESCC fulfilling the Fluhmann diagnostic criteria and staged as FIGO 2023 IICm–p53abn. Case report A 62–year–old woman, gravida 3 para 3, was transfered to our institution with a three–month history of postmenopausal bleeding. Prior to presentation, she had been evaluated at an outside hospital. Tumor marker assessment revealed an elevated squamous cell carcinoma antigen (SCC-Ag) level of 3.17 ng/mL (reference range: 0.00–1.5 ng/mL), a tumor marker commonly used in the management of squamous cell carcinomas. CA125 and CA19–9 levels were within normal limits. Cervical high–risk human papillomavirus (HPV) testing was performed using the Hybrid Capture method and was negative, and liquid–based cytology demonstrated atypical squamous cells of undetermined significance (ASC–US). Hysteroscopic examination at the initial hospital showed a slightly atrophic cervix with smooth but congested cervical mucosa, intrauterine fluid accumulation, and friable, clustered tissue involving all four walls of the uterine cavity. Atypical blood vessels were observed. Suction curettage yielded abundant friable tissue fragments and a small amount of fleshy material. However, because the concomitant cervical canal curettage failed to obtain any tissue samples, the extent of cervical involvement could not be clearly determined. Based on these findings, a preliminary diagnosis of endometrial squamous cell carcinoma was suspected. Distinguishing primary endometrial squamous cell carcinoma from cervical squamous cell carcinoma with secondary upward spread is a well-recognized diagnostic challenge, as these entities require markedly different clinical management. At our institution, prior cervical cytology showed ASC-US with negative high-risk HPV testing, and colposcopy-directed cervical biopsy revealed only chronic inflammation, indicating no clear indication for cold knife conization. Therefore, repeat hysteroscopic evaluation combined with endocervical curettage was performed to further assess possible cervical involvement. The repeat examination similarly revealed a smooth but congested cervical mucosa, intrauterine fluid accumulation, and friable exophytic tissue distributed along the four walls of the uterine cavity with atypical vascular patterns (Fig. 1).The initial curettage specimens were submitted for pathological evaluation and were interpreted as exophytic papillary proliferation of squamous epithelium with marked tissue fragmentation. Further immunohistochemical analysis supported a diagnosis of high–grade squamous intraepithelial lesion (HSIL), corresponding to cervical intraepithelial neoplasia grade 3 (CIN 3), presumed to originate from the endocervical canal. However, pathological examination of the endocervical curettage specimen demonstrated only squamous epithelial hyperplasia without evidence of invasive carcinoma. These findings suggested that the primary lesion was more likely to originate from the endometrial cavity rather than the cervix. Accordingly, a diagnosis of primary endometrial squamous cell carcinoma, rather than secondary spread from cervical squamous cell carcinoma, was favored. Following curettage, the patient’s serum SCC level decreased to within the normal range. Hysteroscopic findings. (A) Hysteroscopy revealed friable, clustered tissue involving all four walls of the uterine cavity, accompanied by atypical vascular patterns. (B) The cervical mucosa appeared smooth but congested. Contrast–enhanced pelvic magnetic resonance imaging (MRI) demonstrated enlargement of the uterine cavity with heterogeneous internal signal intensity, along with patchy areas of enhancement on post–contrast images. The cervical stroma remained intact and continuous, with no evidence of stromal invasion. Transvaginal ultrasonography revealed no significant abnormalities. Based on the combined clinical, radiologic, histopathological, and immunohistochemical findings, a preoperative diagnosis of primary endometrial squamous cell carcinoma, FIGO 2023 stage IC was established. The patient underwent extrafascial total hysterectomy with bilateral salpingo–oophorectomy, combined with sentinel lymph node mapping and excision. Intraoperatively, the uterus appeared mildly enlarged. Gross examination of the surgical specimen revealed multiple focal lesions measuring approximately 1 × 1 cm, located at both uterine cornua and the upper segment of the left uterine wall. Tumor-based HPV testing was negative.Final surgical pathology demonstrated a tumor predominantly confined to the endometrial cavity with less than 50% myometrial invasion (Fig. 2). The endocervical mucosa was uninvolved. No lymphovascular space invasion was identified. All examined regional lymph nodes were negative for metastasis, and no distant metastatic disease was detected. The final diagnosis was moderately differentiated primary squamous cell carcinoma of the endometrium. The pathological findings, including both biopsy and postoperative specimens, were reviewed and confirmed by two senior pathologists. Distinct immunohistochemical profiles were observed in different regions of the specimen. In the cervical squamous metaplastic area, tumor cells demonstrated estrogen receptor (ER) positivity (∼40%), progesterone receptor (PR) negativity, p63 positivity, p40 positivity, Ki–67 labeling index of approximately 30%, p16 negativity, and CK5/6 positivity. In contrast, the endometrial squamous carcinoma component was ER negative, PR negative, p63 positive, p40 positive, with a Ki–67 labeling index of approximately 40%, p16 positivity, and CK5/6 positivity. Histopathological and immunohistochemical findings. (A, B) Hematoxylin and eosin (H&E) staining demonstrated moderately differentiated squamous cell carcinoma arising from the endometrium (A, ×40; B, ×200). (C, D) Immunohistochemical staining showed diffuse expression of squamous markers, including p63 (C) and p40 (D), supporting the diagnosis of primary endometrial squamous cell carcinoma. Molecular profiling showed no pathogenic mutation in the exonuclease domain of the POLE gene, microsatellite stability (MSS), and a mutant–type TP53 alteration (TP53 c.488A > G, p.Y163C). Based on the comprehensive integration of surgical findings, histopathological morphology, immunohistochemical characteristics, and molecular features, the final diagnosis was moderately differentiated endometrial squamous cell carcinoma, FIGO 2023 stage IICm–p53abn. The patient is currently undergoing postoperative adjuvant treatment consisting of paclitaxel plus carboplatin (TC regimen) in combination with vaginal brachytherapy at a local hospital, aiming to enhance radiosensitivity and reduce the risk of recurrence given the extensive intrauterine involvement and p53-abnormal expression, with ongoing regular follow-up. Discussion PESCC remains a diagnostic challenge because of its extreme rarity and its significant overlap with cervical squamous cell carcinoma involving the endometrium. In our case, the initial pathological interpretation favored CIN 3, reflecting the marked histomorphologic and immunophenotypic similarities between PESCC and cervical squamous carcinoma with secondary upward spread. This overlap underscores the limitation of relying solely on histopathology when determining tumor origin. Endocervical curettage was critical in excluding a primary cervical lesion and supporting an endometrial origin, highlighting the importance of comprehensive clinicopathologic correlation in diagnostically ambiguous cases. In the absence of a histology–specific staging system, PESCC is staged according to the FIGO criteria for endometrial carcinoma. The 2023 FIGO revision introduced molecular–integrated staging aligned with The Cancer Genome Atlas (TCGA) molecular subgroups(Berek et al., 2023). However, whether this framework is fully applicable to PESCC remains uncertain, given its rarity and distinct histology. To explore this issue, we reviewed 14 reported cases (2011–2024) with available immunohistochemical and molecular data (Table 1). Table 1Clinicopathologic Features and Molecular Profiles of Published Cases of Primary Endometrial Squamous Cell Carcinoma (PESCC).Author (year)AgeFIGO stageDFS (months)Adjuvant therapyPOLE mutationsMicrosatellite instability statusP53 mutationP16ERPRKi-67CK5/6P63CK7CK20P40HPVPresent case62IICm-p53abnC/T (CBP + PTX) + VBT(−)MSS(+) TP53 c.488A > G, p.Y163C(−)(−)(−)40% (+)(+)(+)N/AN/A(+)(−)Liu, K.H., 2024(Liu et al., 2025)61IBN/AAdjuvant EBRT (50.4 Gy/28F) + brachytherapyN/AN/A(−)N/A(−)(−)N/AN/AN/AN/AN/AN/AN/AZhang HB., 2024(Zhang et al., 2024)62IIIC23yrs, lung metastasisC/T (platinum-based)N/AN/A(−)(+)(−)(−)90% (+)(+)(+)N/AN/A(+)(+) 16, 42, 8357IIIC1>16 msC/T (CBP + PTX)N/AN/AN/A(−)(+)(−)50% (+)(+)(+)N/AN/A(+)(−)Song L., 2023(Song et al., 2023)56IIIC1N/AC/T + RTN/AMSI-HN/A(+)N/AN/A70% (+)(+)N/A(+)N/A(+)(−)Fanni, D., 2022 (Fanni et al., 2022)73IIIC1(pT1bN1M0)N/AC/T (CBP + PTX)*4 + EBRTN/AN/A(+)(−)(−)(−)N/AN/AN/AN/AN/AN/AN/AMa, L., 2022 (Ma et al., 2023)73N/A>3 msNormative C/TN/AN/AN/A(+)(+)N/A(+)(+)(+)(+)N/A(+)(−)Caulkins, M., 2022(Caulkins et al., 2022)65IB>3 msC/T (PTX + DDP) *6N/AN/A(+)(−)(−)(−)N/AN/AN/A(+)(−)N/A(−)Zhong, P. P., 2022(Zhong et al., 2022)55N/A>8 msNo adjuvant C/T or RTN/AN/A(−)N/A(−)(−)70% (+)(+)(+)(−)N/AN/A(+)Darre, T., 2019(Darré et al., 2019)28IB(pT1N0M0)>6 msC/T (DTX + CBP) *3N/AN/AN/AN/A(−)(−)50% (+)N/AN/AN/AN/AN/A(+) 16, 18Wu, Q., 2018 (Wu et al., 2018)33IVN/AC/T (CBP + PTX) + RTN/AN/A(+)N/AN/AN/A80% (+)(+)(+)(+)(+)(−)(−)Terada T., 2013(Terada and Tateoka, 2013)72IC (pT1C, N0, M0)>15 msDDP + RT + brachytherapyN/AN/A(+)N/AN/AN/A(+)N/AN/AN/AN/AN/AN/ALee SJ., 2012(Lee and Choi, 2012)54N/A> 13 msRTN/AN/AN/A(+)(−)(−)80%(+)N/A(+)(+)(−)N/A(−)Abbreviations: FIGO, International Federation of Gynecology and Obstetrics; DFS, disease-free survival; MSI-H, microsatellite instability–high; MSS, microsatellite stable; N/A, not available; C/T: chemotherapy; CBP: Carboplatin; PTX: Paclitaxel; DDP: Cisplatin; DTX: Docetaxel; 5-FU: 5-fluorouraci; EBRT: external beam radiation therapy; RT: radiotherapy; VBT: vaginal brachytherapy. Clinicopathologic Features and Molecular Profiles of Published Cases of Primary Endometrial Squamous Cell Carcinoma (PESCC). Abbreviations: FIGO, International Federation of Gynecology and Obstetrics; DFS, disease-free survival; MSI-H, microsatellite instability–high; MSS, microsatellite stable; N/A, not available; C/T: chemotherapy; CBP: Carboplatin; PTX: Paclitaxel; DDP: Cisplatin; DTX: Docetaxel; 5-FU: 5-fluorouraci; EBRT: external beam radiation therapy; RT: radiotherapy; VBT: vaginal brachytherapy. Immunohistochemically, PESCC demonstrates a stable squamous phenotype, with CK5/6 and p63 positivity observed in 100% of assessed cases and p40 positivity in 83.3%. Hormone receptor expression was largely absent. Estrogen receptor positivity was detected in only 20% of cases, while progesterone receptor expression was not reported in the available cases. This pattern differs from conventional endometrioid endometrial carcinoma, which commonly exhibits hormone receptor expression. Aberrant p16 expression was identified in 50% of tumors. In cervical squamous cell carcinoma, diffuse p16 overexpression is commonly used as a surrogate marker of high–risk HPV–associated oncogenesis. However, in the reported PESCC cases, p16 positivity was not consistently accompanied by documented HPV infection. These findings indicate that p16 expression in PESCC does not consistently correlate with documented HPV infection, and its biological significance in this context remains uncertain. The underlying biological mechanisms remain unclear and require further investigation. Molecular data remain limited. POLE mutations were not identified, microsatellite instability was rare, and abnormal p53 expression was observed in 62.5% of evaluated tumors, suggesting a relatively frequent involvement of the p53 pathway in reported cases. Notably, under the 2023 FIGO molecular–integrated staging system, p53–abnormal tumors confined to the uterus are upstaged within stage I due to their established adverse prognostic significance in endometrial adenocarcinoma. However, whether this prognostic implication can be directly extrapolated to PESCC remains uncertain. Despite the observed frequency of p53 abnormalities, available outcome data in PESCC do not uniformly demonstrate the aggressive clinical course typically associated with p53-abnormal endometrial adenocarcinoma. Taken together, PESCC appears to differ from conventional endometrial adenocarcinoma in both immunophenotypic features and molecular distribution. In our focused review of 14 reported cases, PESCC is characterized by diffuse expression of squamous markers such as CK5/6, p63 and p40, alongside loss of hormone receptor expression, in contrast to the hormone–dependent phenotype commonly observed in endometrial adenocarcinoma(Smith et al., 2018). The biological and prognostic implications of alterations in the p53 and p16 pathways may not fully correspond to those defined in common endometrial carcinoma subtypes. Additional well–characterized cases with standardized molecular profiling are required to clarify the applicability and prognostic calibration of current molecular staging systems in this rare entity. Adjuvant treatment strategies varied across reported cases, including chemotherapy, radiotherapy, and combined approaches, reflecting the rarity of primary endometrial squamous cell carcinoma and the lack of standardized management guidelines (Table 1). Further accumulation of cases is needed to better define optimal treatment strategies for this rare entity. CRediT authorship contribution statement Yifei Zhan: Writing – review & editing, Writing – original draft, Visualization, Investigation, Formal analysis, Data curation. Xiaojing Guo: Writing – review & editing, Validation, Resources, Investigation. Jinling Zhang: Writing – review & editing, Supervision, Project administration, Funding acquisition, Conceptualization. Funding The research was supported by a grant from the Guangdong Basic and Applied Basic Research Foundation. (2023A1515012216). Ethics Statement. This study was approved by the Institutional Review Board of Shenzhen People's Hospital, Shenzhen, China (Approval LL-KY-2026085-01). The study was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from the patient for publication of this case report and any accompanying images. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. References